Chromium for PCOS

Verdict: Weak, disputed evidence for PCOS

Chromium may modestly nudge a few metabolic markers in PCOS, but the evidence is weak and disputed, and no health authority recommends it for the condition. It is not a substitute for proven first-line care, and better-supported options such as inositol exist.

C 🟠 C Weak Evidence Disputed

🔬Why this grade7-layer evidence engine

The supportive signal comes almost entirely from small trials of chromium picolinate (200-1000 mcg/day). Meta-analyses report modest drops in BMI (about 0.87-1.13 kg/m2), fasting insulin (roughly -1.3 mIU/L) and free testosterone (PMID 30180497, PMID 29307112, PMID 28595797, PMID 41067797), echoed by individual RCTs (PMID 26279073; PMID 24639797, where chromium roughly matched metformin). But two foundational pilots were tiny and underpowered (PMID 16730719, n=5; PMID 16359984, n=6), and the meta-analyses largely re-pool the same single-center Iranian trials rather than independent evidence streams.

The grade lands at weak (C) and disputed because the wins are on surrogate markers, not the outcomes that matter most in PCOS such as ovulation, pregnancy or live birth, and effects on fasting glucose, total testosterone and lipids were null. No large independent RCT or Cochrane review exists.

Regulators and clinicians are notably cautious. The FDA calls a chromium-insulin link 'highly uncertain'; EFSA found no evidence of benefit and does not deem chromium essential; NIH ODS rates its weight effects as clinically negligible; Harvard is unsupportive and Cleveland Clinic skeptical. Crucially, the 2023 international PCOS guideline (Endocrine Society/ASRM) discusses inositol but does not mention chromium, so it remains, at best, an unproven adjunct.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.56
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
C · Disputed
Confidence
61%
Broadly consistent
Evidence level
E2
Multiple high-quality MAs (≥2 independent, consistent)

How strongly each layer supports this effect

lower = less supportive
L5 Clinical bodiesAuthoritative stance
0.28
L1 ExamineGlobal benchmark
0.50
L11 AI re-checkIndependent read
0.50
L3 MechanismPlausibility
0.65
L2 PubMedPrimary literature
0.75
Against Mixed Supports
View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.556
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 高品質 SR/MA 顯示 positive (2 篇 > 0 negative)
  4. tier_strict_requirement_check — | B→C 因 scope.conflation_risk=true 且 L11 獨評較低 (B7-2 tier cap)
  5. detect_disputes — 偵測到 1 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (8)L2 · primary research & systematic reviews

Effect of chromium supplementation on metabolic profiles in PCOS: A systematic review and meta-analysis of RCTs
PMID: 30180497 2018 統合分析 n = 351
Finding: Chromium significantly reduced insulin (WMD -1.31 mIU/L, 95%CI -2.42 to -0.21), HOMA-IR (WMD -0.34, 95%CI -0.65 to -0.04) and BMI (WMD -0.87 kg/m2); no significant effect on fasting glucose, total testosterone, or lipid sub-fractions; trend toward improved hirsutism (Ferriman-Gallwey).
Academic Effect size: [object Object]
View on PubMed
The Influences of Chromium Supplementation on Glycemic Control, Markers of Cardio-Metabolic Risk, and Oxidative Stress in Infertile Polycystic ovary Syndrome Women Candidate for In vitro Fertilization: a Randomized, Double-Blind, Placebo-Controlled Trial
PMID: 29307112 2018 統合分析 n = 286
Finding: Pooled analysis showed chromium reduced BMI (WMD -1.13, 95%CI -2.06 to -0.20), free testosterone (WMD -1.05 pg/mL, 95%CI -1.93 to -0.17) and increased free fatty acids; no effect on insulin, HOMA-IR, glucose or oxidative stress markers in pooled analysis. Heterogeneity high.
Academic Effect size: [object Object]
View on PubMed
Chromium supplementation and polycystic ovary syndrome: A systematic review and meta-analysis
PMID: 28595797 2017 系統性回顧 n = 215
Finding: Chromium picolinate appears to improve insulin sensitivity, BMI and ovulation in PCOS patients but findings limited by small samples and heterogeneous dosing; suggests potential adjunct role but evidence not yet definitive.
Academic
View on PubMed
Chromium Supplementation and the Effects on Metabolic Status in Women with Polycystic Ovary Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial
PMID: 26279073 2015 RCT (double-blind) n = 64
Finding: Chromium significantly decreased free testosterone (-0.7 vs +0.1 pg/mL, p=0.02), hs-CRP (p=0.02), MDA (p=0.01) and increased GSH (p=0.01) and TAC (p=0.04) vs placebo; no effect on SHBG or other androgens.
Academic Effect size: [object Object]
View on PubMed
Comparing the effect of metformin and chromium picolinate on PCOS: a randomized clinical trial (Amooee)
PMID: 24639797 2013 RCT (double-blind) n = 92
Finding: Both arms produced significant improvement in BMI, fasting insulin and ovulation rate; metformin superior on FSH/LH normalization while chromium showed comparable effects on insulin sensitivity and BMI with better tolerability; both agents improved ovulation (p<0.05 within group).
Academic
View on PubMed
Chromium picolinate improves insulin sensitivity in obese subjects with polycystic ovary syndrome (Lydic)
PMID: 16730719 2006 隨機對照試驗 n = 5
Finding: Chromium picolinate 1000 mcg/d improved glucose disposal rate by 38% (p<0.05) in obese PCOS women; pilot study with very small n; no effect on ovulation/menstrual frequency in 8 weeks.
🟠 Limited quality Academic Effect size: [object Object]
View on PubMed
Effect of chromium supplementation on insulin resistance and ovarian and menstrual cyclicity in women with polycystic ovary syndrome
PMID: 16359984 2005 RCT (double-blind) n = 6
Finding: Chromium picolinate 200 mcg/d for 16 weeks improved insulin sensitivity (M-value) by 35% in PCOS subjects (n=3) with no change in placebo (n=3); pilot data, no menstrual/ovulatory benefit demonstrated; underpowered.
🟠 Limited quality Academic Effect size: [object Object]
View on PubMed
Therapeutic effects of chromium supplementation on women with polycystic ovarian syndrome: A systematic review and meta-analysis
PMID: 41067797 2025 統合分析 n = 274
Finding: Chromium reduced BMI (WMD -0.87 kg/m2, 95%CI -1.55 to -0.18) but had no significant effect on weight, total cholesterol, LDL-C, HDL-C, triglycerides or hs-CRP in pooled analysis; effect on BMI driven by lower-dose subgroups.
Academic Effect size: [object Object]
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Cautious
One small study suggests that chromium picolinate may reduce the risk of insulin resistance, and therefore possibly may reduce the risk of type 2 diabetes. FDA concludes, however, that the existence of such a relationship between chromium picolinate and either insulin resistance or type 2 diabetes is highly uncertain. source↗
L4b EU EFSA
Against
The Panel concludes that there is no evidence of beneficial effects associated with chromium intake in healthy subjects ... no Average Requirement (AR) and Population Reference Intake (PRI) can be defined; chromium is not an essential nutrient. source↗
L4c UK NHS
Cautious
You should be able to get all the chromium you need by eating a varied and balanced diet. Around 25 micrograms of chromium a day should be enough for adults. Having 10mg or less a day of chromium from food and supplements is unlikely to cause any harm. source↗
L4d TW TFDA / 衛福部
Supportive
每日食用量中,其鉻之總含量不得高於200微克 source↗
L4e WHO
Not addressed
Chromium[VI] is carcinogenic to humans (Group 1). Metallic chromium and chromium[III] compounds are not classifiable as to their carcinogenicity to humans (Group 3). source↗
L5a NIH Office of Dietary Supplements
Cautious
Research suggests that chromium supplementation reduces body weight and body fat percentage to a very small, but statistically significant, extent. However, these effects have little clinical significance. source↗
L5c Cleveland Clinic
Cautious
L5d Harvard Health
Against
PMID 100% verifiedevery citation checked via NCBI Entrez
🔬8 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-pcos-INT-chromium-001 繁體中文版 →